Open innovation: The new face of pharmaceutical research and development

Expert Review of Clinical Pharmacology

Volumn 5, Issue 5, 2012, Pages 481-483

  Getz, Kenneth A ^a   Kaitin, Kenneth I ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

drug development; open innovation; partnerships; pharmaceutical; pharmaceutical industry; research and development

Indexed keywords

COOPERATION; DRUG COST; DRUG DEVELOPMENT; DRUG INDUSTRY; EDITORIAL; HEALTH CARE NEED; HUMAN; INVESTMENT; PHARMACEUTICS; PUBLIC-PRIVATE PARTNERSHIP; WORKLOAD;

BIOMEDICAL RESEARCH; DRUG DISCOVERY; HUMANS; TECHNOLOGY, PHARMACEUTICAL;

EID: 84868540337     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/ecp.12.44     Document Type: Editorial

References (16)

1. Pammolli F, Magazzini L, Riccaboni M. The productivity crisis in pharmaceutical R&D. Nat. Rev. Drug Discov. 10(6), 428-438 (2011).
2. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 87(3), 272-277 (2010).
3. Kaitin KI, DiMasi JA. Pharmaceutical innovation in the 21st century: new drug approvals in the first decade, 2000-2009. Clin. Pharmacol. Ther. 89(2), 183-188 (2011).
4. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat. Rev. Drug Discov. 8(12), 959-968 (2009).
5. DiMasi JA, Grabowski HG. The cost of biopharmaceutical R&D: is biotech different? Manage. Decis. Econ. 28(4-5), 469-479 (2007).
6. World Preview 2016 Report. Evaluate Pharma, DE, USA (2010).
7. Getz KA, Zuckerman R, DiMasi JA, Kaitin KI. Drug development portfolio and spending practices after mergers and acquisitions. Drug Info. J. 43(4), 493-500 (2009).
8. Getz KA, Campo RA, Kaitin KI. Variability in protocol design complexity by phase and therapeutic area. Drug Info. J. 45(4), 413-420 (2011).
9. Getz K, Zuckerman R, Cropp A, Hindle A, Krauss R, Kaitin K. Measuring the incidence, causes, and repercussions of protocol amendments. Drug Info. J. 45(4), 265-275 (2011).
10. Kaitin K (Ed.). Rising demand is expanding scope and workload of regulatory affairs function. Tufts CSDD Impact Reports 12(2), (2010).
11. Getz KA, Vogel Jr. Successful outsourcing: tracking global CRO usage. Appl. Clin. Trials Online 17, 39-44 (2009).
12. Hunter J. Is open innovation the way forward for big pharma? Nat. Rev. Drug Discov. 2(9), 87-88 (2010).
13. Kaitin KI. 21st century bioinnovation: academic-industry partnerships are increasingly important in biopharmaceutical innovation. Pharma. Technol. 35(6), 32 (2011).
14. Getz K. FIPNet: pharma's new, sexy, but not yet ready for print-time model. Appl. Clin. Trials (Suppl.), 10-16 (2009).
15. Kaitin KI. Creating innovation nodes to meet unmet medical needs: pharma companies must balance demand for new drugs while facing reduced R&D spending. Pharma. Technol. 35(12), 27 (2011).
16. Kaitin KI. Deconstructing the drug development process: the new face of innovation. Clin. Pharmacol. Ther. 87(3), 356-361 (2010).